Rose is an associate editorial director at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Clostridioides difficile Infection May Be Underdiagnosed in Health Care Facilities, Study Finds
A study of hospitals and long-term care facilities in Louisville, Kentucky, found low rates of Clostridioides difficile testing in patients with new-onset diarrhea who are frequently infected.
Review Addresses Antifungal Prophylaxis in AML and Provides Guidance for Novel Agents
Patients with acute myeloid leukemia (AML) who have undergone intensive chemotherapy are at a very high risk for invasive fungal disease, and a changing treatment landscape warrants further research on drug-drug interactions and outcomes.
Review Highlights Treatment Landscape, Insights on Pregnancy Management for ET or PV
Polycythemia vera and essential thrombocythemia are both slow-progressing conditions and treated mainly with symptom management, but novel agents and gene targets have changed the landscape in recent years.
SHEA Updates Guidelines for Central Line-Associated Bloodstream Infection Prevention in Hospitals
Preventing health-care–associated infections in acute-care hospitals is crucial for patient well-being and health care cost burden, and comprehensive guidelines based on current research are an important aspect of prevention.
Novel Therapies Targeting Vasoconstriction and Vascular Remodeling May Improve Outcomes in PAH
Drugs currently marketed for pulmonary arterial hypertension have been able to extend the lives of patients but have shown limitations in their ability to prevent or reverse the disease. A novel combination approach may hold promise in future treatments.
RNA Sequencing Identifies Novel, Specific Biomarkers in Pterygia
While risk factors for pterygia are well-known, the underlying disease mechanisms have not been fully clarified in past studies. A new analysis using RNA sequencing pinpointed ptergyia-specific biomarkers and potential therapeutic targets.
AKR1C3 Expression May Hold Potential as a Biomarker, Clinical Target in T-ALL
Aldo-keto reductase 1C3 (AKR1C3) has been identified as a potential biomarker and target in several cancers, and a recent study found it to be a potential biomarker in T acute lymphoblastic leukemia/lymphoma (T-ALL).
Novel Internet-Based Hospital-to-Home Model for Nutritional Nursing Effective in Patients With CKD
Continual nutrition modification is crucial in patients with moderate to advanced chronic kidney disease (CKD), and more interactive at-home solutions hold potential to improve nutritional nursing models after hospital discharge.
Mesenchymal Stem Cells Induce Cell Proliferation, Inhibit Dexamethasone Effectiveness in MM
Mesenchymal stem cells are known to promote tumor growth and metastasis in multiple myeloma (MM), but a recent study found they may also inhibit the effects of the corticosteroid dexamethasone, a common medication for the hematologic malignancy.
Neurocognitive Changes After CAR T-Cell Therapy for NHL Similar to Other Cancers
With an increasing number of longer-term survivors treated with chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma (NHL), more research is needed to confirm its effects on neurocognitive performance.
LMOD3 Gene Variant Identified in Hypersomnolence Case With Potential Kleine-Levin Syndrome
Kleine-Levin syndrome is rare and difficult to diagnose, especially when symptoms are atypical. Recent research points to LMOD3 variations as a potential diagnostic marker if confirmed by further research.
Examining Changes in STEMI Treatment Strategies and Outcomes in CKD Over Time
Despite underrepresentation in clinical trials of acute coronary syndrome treatments, a recent study suggests treatment strategies and outcomes in chronic kidney disease patients with ST-elevation myocardial infarctions (STEMI) have improved over time.
Study Finds LCOR May Be a Viable Target to Increase Efficacy of Immunotherapy in TNBC
Therapy resistance remains a challenge with immune checkpoint inhibitors, and a new study proposes targeting ligand-dependent corepressor (LCOR) in addition to known immune targets to improve outcomes.